Related references
Note: Only part of the references are listed.Increased Mortality Risk in Patients With Primary and Secondary Adrenal Insufficiency
Kanchana Ngaosuwan et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
Takashi Ikeda et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2021)
How we treat endocrine complications of immune checkpoint inhibitors
S. A. Paschou et al.
ESMO OPEN (2021)
Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study
Tomoko Kobayashi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review
Maria Stelmachowska-Banas et al.
ENDOCRINE CONNECTIONS (2020)
A retrospective analysis of eosinophilia as a predictive marker of response and toxicity to cancer immunotherapy
Tharani Krishnan et al.
FUTURE SCIENCE OA (2020)
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B. Escudier et al.
ANNALS OF ONCOLOGY (2019)
Eosinophilia during treatment of immune checkpoint inhibitors (ICIs) to predict succeeding onset of immune-related adverse events (irAEs).
Rika Kizawa et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis
Alexander Faje et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2019)
Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma
Eva Kassi et al.
CANCER MEDICINE (2019)
Delivery technologies for cancer immunotherapy
Rachel S. Riley et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Management of Hypopituitarism
Krystallenia Alexandraki et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society
Hiroshi Arima et al.
ENDOCRINE JOURNAL (2019)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens A Systematic Review and Meta-analysis
Romualdo Barroso-Sousa et al.
JAMA ONCOLOGY (2018)
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer
J. C. Osorio et al.
ANNALS OF ONCOLOGY (2017)
Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies
David J. Byun et al.
NATURE REVIEWS ENDOCRINOLOGY (2017)
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review
L. Khoja et al.
ANNALS OF ONCOLOGY (2017)
Immune Checkpoint Blockade in Cancer Therapy
Michael A. Postow et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Diagnosis and management of adrenal insufficiency
Irina Bancos et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
Adrenal insufficiency
Evangelia Charmandari et al.
LANCET (2014)
Investigation of the freely available easy-to-use software 'EZR' for medical statistics
Y. Kanda
BONE MARROW TRANSPLANTATION (2013)
Share Paper
